Clinical trials: Autoimmune Bullous Disease
Pemphigoid, Bullous
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Randomized, placebo-controlled, double-blind study evaluating the effect of anti-IL-5-therapy in patients with bullous pemphigoid.
- Trial name
- NCT01705795
- Testing
- Mepolizumab (a-IL-5 antibody)
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bullous Pemphigoid
The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors
The investigators conducted a prospective study which included all patients diagnosed with biopsy-proven BP in the Dermatology Department of Attikon hospital between April 1, 2009 and December 31, 2019.
- Trial name
- NCT04469582
- Where
- Greece
- Volunteers
- 113 people
- Sponsor
- University of Athens
Pemphigoid, Bullous
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
- Trial name
- NCT04499235
- Testing
- Mometasone furoate, AKST4290
- Where
- 8 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Alkahest, Inc.
Bullous Pemphigoid
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity.
- Trial name
- NCT01688882
- Testing
- QGE031
- Where
- 9 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Bullous Pemphigoid
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
To evaluate the efficacy of rituximab combined with omalizumab in achieving sustained complete remission, evaluated by Bullous Pemphigoid Disease Area Index (BPDAI) in patients with bullous pemphigoid (BP) at Week 24 in patients…
- Trial name
- NCT04128176
- Testing
- Rituximab combined with Omalizumab
- Where
- United States
- Sponsor
- University of California, Davis
Bullous Pemphigoid
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and a substantial increase in incidence in people older than…
- Trial name
- NCT03286582
- Testing
- AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- TWi Biotechnology, Inc.
Bullous Pemphigoid, Pemphigoid
Ixekizumab in the Treatment of Bullous Pemphigoid
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin…
- Trial name
- NCT03099538
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Bullous Pemphigoid
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year.
- Trial name
- ARABUL (NCT00802243)
- Testing
- leflunomide
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Limoges
Bullous Pemphigoid
Telederm and Bullous Pemphigoid
The purpose of the study is to improve the quality of future clinical trials in bullous pemphigoid (BP), the investigators will monitor repeated measurement data from patients with BP on standard-of-care treatments at four week…
- Trial name
- NCT04728854
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Bullous Pemphigoid
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular.
- Trial name
- RECOPB (NCT02360202)
- Testing
- Impedance analysis, Clobetasol Propionate cream treatment
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
Whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact on quality of life have been little studied.
- Trial name
- PRURIPB (NCT03272958)
- Where
- 16 sites in France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Brest
Bullous Pemphigoid
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
The development of Auto Immune bullous Diseases (AIBD) results from a complex interaction between innate and adaptive immune systems.
- Trial name
- IPH (NCT04563923)
- Testing
- Avdoralimab (IPH5401), Control
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Periodontal Diseases, Psoriasis
Periodontal Status in Patients With Chronic Skin Diseases
Objective: This study aimed to evaluate and compare the periodontal status of chronic skin disease (CSD) patients with healthy controls. Material and method: 109 patients and 37 healthy subjects were included in this study.
- Conditions
- Periodontal Diseases, Psoriasis, Atopic Dermatitis, Autoimmune Bullous Dermatosis
- Trial name
- NCT06073613
- Testing
- oral health status
- Where
- Vietnam
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Pemphigus Vulgaris, Bullous Dermatoses
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
This study will compare the pattern of Th17 immune response in active and inactive pemphigus subjects. Skin and serum samples will be taken at the moment of enrollment.
- Conditions
- Pemphigus Vulgaris, Bullous Dermatoses, Autoimmune Diseases
- Trial name
- NCT04096222
- Where
- 2 sites in Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Pemphigoid, Bullous
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
This study investigates the differences of Eosinophil Cationic Protein, Tumor Necrosis Factor-alpha and Anti-BP180-NC16A IgG levels of blister fluids in Bullous Pemphigoid patients which appeared before and under treatment…
- Trial name
- BP (NCT03856840)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Mahmut Can Koska
Bullous Pemphigoid
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
- Trial name
- FJORD (NCT04612790)
- Testing
- Benralizumab
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 67 people
- Sponsor
- AstraZeneca
Bullous Pemphigoid (BP)
Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC)
Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity.
- Trial name
- BP-EPIC (NCT07649486)
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul Training and Research Hospital
Bullous Pemphigoid, Pruritus
Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission
The following is the investigators hypothesis regarding the pruritus of BP patients during remission. Anti-BP 180 IgE binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by…
- Trial name
- NCT01265082
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Bullous Dermatoses, Psoriasis
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with…
- Conditions
- Bullous Dermatoses, Psoriasis, COVID-19 Vaccines
- Trial name
- NCT05406908
- Testing
- tozinameran
- Where
- Thailand
- Volunteers
- 109 people
- Sponsor
- Mahidol University
Pemphigoid, Pruritus
Pruritus and Pemphigoid in Nursing Home Patients
The primary objective of this observational study is to describe the prevalence of pruritus and pemphigoid in nursing home patients.
- Trial name
- SSENIOR (NCT02823067)
- Testing
- Blood sample
- Where
- Netherlands
- Volunteers
- 125 people
- Sponsor
- M.F. Jonkman